✦ LIBER ✦

Longterm Followup Assessment of a HER2/neu Peptide (E75) Vaccine for Prevention of Recurrence in High-Risk Prostate Cancer Patients

✍ Scribed by Jeremy D. Gates; Mark G. Carmichael; Linda C. Benavides; Jarrod P. Holmes; Matthew T. Hueman; Michael M. Woll; Constantine G. Ioannides; Craig H. Robson; David G. McLeod; Sathibalan Ponniah; George E. Peoples

Book ID: 113678955
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 288 KB
Volume: 208
Category: Article
ISSN: 1072-7515
DOI: 10.1016/j.jamcollsurg.2008.10.018

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase IB trial of the Her2/neu peptide (

Phase IB trial of the Her2/neu peptide (E75) vaccine for optimal dosing in node-negative breast cancer patients

✍ E.A. Mittendorf; S. Khoo; Z.A. Dehqanzada; M.T. Hueman; C.E. Storrer; K.A. Harri 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 88 KB

Comparison of immunological responses in

Comparison of immunological responses in node-positive and node-negative breast cancer patients receiving a HER2/neu E75 peptide vaccine

✍ M. T. Hueman; J. M. Gurney; C. E. Storrer; L. Kotula; K. Jackson; M. Wilson; C. 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 296 KB

Clinical trial results of the HER-2/neu

Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients : From US Military Cancer Institute Clinical Trials Group Study I-01 and I-02

✍ Elizabeth A. Mittendorf; Guy T. Clifton; Jarrod P. Holmes; Kevin S. Clive; Rites 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 1016 KB

Clinical and Immunologic Responses of HL

Clinical and Immunologic Responses of HLA-A3+ Breast Cancer Patients Vaccinated with the HER2/neu-Derived Peptide Vaccine, E75, in a Phase I/II Clinical Trial

✍ Ritesh Patil; Guy T. Clifton; Jarrod P. Holmes; Asna Amin; Mark G. Carmichael; J 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 728 KB

A more sensitive immunological monitorin

A more sensitive immunological monitoring tool for cancer vaccine trials: A direct comparison of HLA-A2 dimer and tetramer molecules in measuring the in vivo immune response to a HER2/neu peptide-based vaccine (E75) in prostate and breast cancer patients

✍ Matthew T. Hueman; Jennifer Gurney; Michael Woll; Catherine Storrer; David McLeo 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 53 KB